Development of a polymerase chain reaction assay for the detection of Mycoplasma bovis by Pinnow, Cole Curtis
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
1-1-1999
Development of a polymerase chain reaction assay
for the detection of Mycoplasma bovis
Cole Curtis Pinnow
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Microbiology Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Pinnow, Cole Curtis, "Development of a polymerase chain reaction assay for the detection of Mycoplasma bovis" (1999). Retrospective
Theses and Dissertations. 17828.
https://lib.dr.iastate.edu/rtd/17828
Development of a polymerase chain reaction assay for 
the detection of Mycoplasma bovis 
by 
Cole Curtis Pinnow 
A thesis submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
MASTER OF SCIENCE 
Major: Microbiology 
Major Professor: Ricardo F. Rosenbusch 
Iowa State University 
Ames, Iowa 
1999 
11 
Graduate College 
Iowa State University 
This is to certify that the Master's thesis of 
Cole Curtis Pinnow 
has met the thesis requirements of Iowa State University 
Signatures have been redacted for privacy 
111 
TABLE OF CONTENTS 
CHAPTER 1. GENERAL INTRODUCTION 1 
Thesis Organization 1 
Introduction to Mycoplasmas 1 
CHAPTER 2. LITERATURE REVIEW 4 
Mycoplasma bovis 4 
Mycoplasma bovis and Mycoplasmal Mastitis 9 
Detection Methods for Mycoplasma bovis 16 
CHAPTER 3. DETECTION OF MYCOPLASMA BOVIS IN PRESERVATIVE- 22 
TREATED FIELD MILK SAMPLES BY NESTED PCR 
AMPLIFICATION OF OLIGOPEPTIDE PERMEASE GENES 
Abstract 22 
Introduction 23 
Materials and Methods 24 
Results 31 
Discussion 35 
Acknowledgement 38 
References 38 
CHAPTER 4. GENERAL SUMMARY 43 
APPENDIX A. STUDIES ON THE VIABILITY OF MYCOPLASMA BO VIS 46 
CULTURE SAMPLES 
APPENDIX B. THE INTERACTION OF VARIABLE SURF ACE 50 
LIPOPROTEIN A (VSPA) IN MYCOPLASMA BOVIS WITH 
CULTURED MAMMALIAN CELLS 
LITERATURE CITED 60 
ACKNOWLEDGEMENTS 76 
1 
CHAPTER 1. GENERAL INTRODUCTION 
Thesis Organization 
The thesis has been written following the chapter format required for including 
a publication. This introduction, and a review of the literature, are followed by a 
publication, which was submitted to the Journal of Clinical Microbiology. A general 
conclusion and two appendixes of supplementary work, performed by the 
candidate, are also included. The thesis concludes with a list of the references which 
were cited throughout the text, excluding those used in the submitted publication. 
Those references are independently located at the end of Chapter 3. 
Introduction to Mycoplasmas 
Mycoplasmas are the smallest known, free-living organisms in existence (82). 
While the term "mycoplasma" has been used to refer to any species within 
Mollicutes, the genus Mycoplasma is one of a total of eight geme in the class (99). 
Mycoplasmas are distinguished from other bacteria by their minute size and 
total lack of a cell wall (97). They are tiny enough to pass through 0.45µm pore 
diameter filters (129), and it was originally thought that most mycoplasma species 
have a genome size between 600 and 800 kbp (96). The later use of pulse-field gel 
electrophoresis (95), a much more accurate procedure, presented new results 
showing a great array of genome sizes ranging from Mycoplasma genitalium, with 580 
kb, to 1,380 kb for Mycoplasma mycoides subsp. mycoides LC (84). 
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Genome sizes vary not only within this genus, but, also among strains of the 
same species. One of the reasons accounting for this variation is the presence of 
repetitive regions, consisting of segments of protein genes, differing in size and 
number, or genomes containing insertion sequence elements (35). In Spiroplasma 
citri, for example, integration of viral species accounts for 150 kb, or 1I12 of the 
entire genome (8). 
Although there is no direct correlation between genome size and in vitro growth 
(131), the limited genomic resources of the mycoplasma do correlate with limited 
metabolic abilities (92). The mycoplasma cell contains only the minimum sets of 
organelles and metabolic pathways essential for cellular growth and replication (80). 
Although some mycoplasmas are commensals, most species are pathogens and 
require a close association with their host cell surfaces (130). 
Since mycoplasmas have a single membrane, they predominate in a spherical 
shape (103). Many Mollicutes, however, have been shown to exhibit a variety of 
morphologies, including trilaminar (32), filamentous (21, 25)~ and helical shapes 
(128). The ability to sustain such form, in the absence of a cell wall, has led to the 
discovery of the cytoskeleton (79) and motility (135). 
The lack of a cell wall, has provided mycoplasmas with other characteristics 
which have been associated to the genus. When grown on solid media, the 
mycoplasma group has a "fried egg" colonial appearance (105). They are sensitive 
to lysis by osmotic shock, alcohols, organic solvents, detergents, or antibody and 
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complement (96), and have total resistance to penicillin and other antibacterial 
substances that degrade or specifically inhibit peptidogycan synthesis (36). 
These characteristics of small cell size, close association to mammalian cells, and 
resistance to antibiotics, have traditionally been used to isolate and identify the 
various mycoplasmal species (133). However, rapid developments in genome-
sequencing methodologies have been facilitating the trend of basing bacterial 
identification, taxonomy, and species definition on molecular data and phylogeny, 
thereby decreasing the use of serological analysis in species and strain identification 
and classification (103). The introduction of molecular tools to taxonomy, including 
the comparison and use of conserved gene sequences (77), DNA hybridization (27), 
and genomic restriction patterns (102), has already been found to be an effective way 
of identifying new species and has seen use in strain identification (99). 
Since the successful application of genomic analysis methodology has led to the 
identification of uncultured mycoplasma-like organisms as bona fide Mollicutes (84), it 
only seems logical that the methodology for diagnostic identification of these 
organisms follow a similar move away from culture and serology. The main 
objective of this research project was to develop an optimal molecular technique for 
the species-specific identification of Mycoplasma bovis. 
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CHAPTER 2. LITERATURE REVIEW 
Among the more than twenty species belonging to the class Mollicutes which 
have been isolated from cattle so far, Mycoplasma bovis is the most important 
aetiological agent of bovine mycoplasmosis in Europe and North America 
(Pfiitzner and Sachse, p.1477, 1996). 
Mycoplasma bovis 
In 1963, an English strain of Mycoplasma bovigenitalium became the first reported 
species of mycoplasma to cause mastitis (119). At the same time, a more severe form 
of mastitis began appearing on the East coast of the United States (46, 67), caused by 
a previously uncharacterized mycoplasma. This isolated mycoplasma was first 
referred to as Mycoplasma agalactiae subsp. bovis, also called Mycoplasma bovimastitidis 
(60), but was characterized as a new species based upon its phenotypic 
characterization and by nucleic acid hybridization (4). Since its discovery, M. bovis 
has appeared all over the world, including all of North America, most of Europe, 
and some Asian countries (62). 
M. bovis is thought to be highly adapted to cattle, and isolation from small 
ruminants is a very rare event (88). However, M. bovis has been localized at sub-
clinical levels in other hosts, such as mice (2), goats (26, 104), swine, horses, geese, 
ducks, (120), and humans (76). Injection of M. bovis into sheep resulted in clinical 
pneumonia and mastitis only when pathogen-free lambs (16) and the udders of ewes 
were used (17). 
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In cattle, the clinical picture of M. bovis infection supports the position of 
damage due to host immune and inflammatory responses (63). The organism has 
been known to cause damage through attachment to host cells (126) and like other 
mycoplasmas, is presumed to cause toxicity by deprivation of nutrients from, or 
alteration of, metabolites of the host cell (116) in addition to direct toxic effects by 
the mycoplasmal cell components (41). 
Transport 
Due to their small genome size, it is no surprise that mycoplasmas lack many 
biosynthetic pathways as evidenced by their dependent supply of many nutrients 
from growth medium or their host (40). Without the ability to synthesize amino 
acids, it was thought that the transport system of mycoplasmas was extensive (111). 
However, sequence analysis of mycoplasmas has shown that they have a very low 
absolute number of putatively identified genes encoding for transport and, when 
compared with other bacteria, do not have a greater percentage of transport genes. 
Mycoplasma pneumoniae and M. genitalium have 6.5 and 7.1 percent of their total 
genes encoding for transport, while Haemophilius influenzae has 7.2 percent (103). 
Possible reasons for how an organism such as M. bovis, which is so dependent 
on substrates, can survive with such a limited number of transport systems has been 
debated. Clearly one advantage is the presence of only one permeability barrier in 
the wall-less bacteria (110). In the case of amino acid transport, it is thought that a 
low substrate specificity plays a role. The M. pneumoniae transporter family 
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sequences have high homology matches with many different substrate specificities 
(52). Sequence analysis of M. genitalium and M. pneumoniae (40, 52) have confirmed 
earlier work which showed that mycoplasmas have amino acid transport systems 
which are similar in function to those found in other organisms (101). 
The ABC transporter systems of mycoplasmas contain two ATP binding 
domains, two membrane spanning- and one substrate-binding domain, all of which 
are usually present on separate polypeptides. These systems are involved in the 
import and export of a large variety of substrates, including sugars, peptides, 
proteins, and toxins. In addition, the deduced amino acid sequence of Mycoplasma 
hyopneumonia ABC system proteins have been shown to have homology with a 
eukaryotic multi-drug resistance protein family (15). 
Although M. genitalium and M. pneumonia have been completely sequenced, to 
the candidate's knowledge, there has not been any identification of the substrate 
binding protein (OppA) for the ABC transporter (52). In other bacteria, the binding 
protein is not only essential to regulating transport, but has also played a role in the 
regulation of other systems, including virulence adhesion factors (91). Mycoplasmal 
binding proteins may have diverged drastically from the homologous proteins in 
other organisms to allow for a broader substrate specificity and, therefore, their 
identification by standard sequence analysis has been extremely difficult (115). It 
has also been suggested that mycoplasmas might receive the substrate binding 
protein directly from the host by close contact (53). Experimental verification is 
needed to answer any questions of the transporter system specificity (39). 
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The ABC transporter four-gene operon in Mycoplasma fermentans has been 
shown to undergo a frameshift mutation and generate high-frequency phase 
variation. One of the four, membrane-associated gene products, a surface exposed 
p78 lipoprotein, presumably serves in substrate binding capacity. This protein is 
subject to phase variation, which might confer alternative substrate specificity and 
transport function, in a gene-saving maneuver (125). Proteins involved in critical 
surface metabolic functions, including exposed transporter components, are likely 
targets of immune-response recognition (34), so selective phase variation of p78 may 
have consequences both for immune evasion and for adaptation of transport 
function in diverse in-host environments (125). 
Antigenic Variation 
Microorganisms have evolved powerful mechanisms for generating phenotypic 
diversity as an efficient strategy for adapting to rapidly responding immune system 
defenses and the broad range of polymorphisms characteristic of different host 
tissues (107). As a result, organisms with these mechanisms of variation can 
generate overwhelming infections because of their relatively short generation time. 
Understanding this variability will help to determine whether a particular pathogen 
is cleared from the host, persists to cause a relatively benign infection, or produces 
severe or even fatal disease (31). 
Of the bovine mycoplasma species, Mycoplasma bovis is second only to 
Mycoplasma mycoides subsp. mycoides SC in pathogenic ability (97). As a pathogenic 
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mycoplasma, M. bovis must deal with the rigors of the immune response and the 
need to be transferred and reestablished in a new host (103). One of the ways this 
can be accomplished is by antigenic variation, the altering of the antigenic character 
of its surface components to enhance the colonization of host tissues and evade 
phagocytosis. 
Antigenic variation can be accomplished in two ways. Microbial pathogens 
may sense host environmental conditions and respond accordingly, using signal 
transduction pathways. Alternatively, the microbial population as a whole may 
spontaneously and randomly generate distinct cell populations with a range of 
antigenic properties to survive a major environmental change or host response (31). 
Regardless, a bacteria with antigenic variation can generate an entire population of 
infecting organisms from a single bacteria (83). 
It is thought that a family of variable surface lipoproteins (Vsps) play a role in 
the pathogenic nature of M. bovis by means of antigenic variation (107). The vsp 
locus is a 16-kb genomic fragment containing thirteen Vsp open reading frames, 
varying in orientation (103). Each vsp gene contains a conserved 190 bp, non-coding 
region at the 5' end, encoding for a ribosome binding site. The first 25 amino acids 
represent a highly conserved lipoprotein signal peptide, containing a positively 
charged amino-terminal region and a central hydrophobic region (71). About 80% 
of V sp molecules are composed of reiterated sequences of different lengths which 
are usually organized as one to four distinct regions of tandem, in-frame blocks 
(103). 
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These antigenic lipoproteins have noncoordinate high-frequency phenotypic 
phase and size variations (9). Studies of field and clinical isolates have suggested 
that different versions of the same vsp gene family exist within a population. This 
allows the species to achieve extensive array of inter-species antigenic variation (10). 
Although little is known about the mechanisms involved in V sp phase variation, 
a representative gene, vspA, has been shown to be involved in chromosomal 
rearrangements. A lineage of clonal isolates, from successive generations, exhibiting 
the ON and OFF phenotypes were analyzed by Southern hybridization blots. There 
was the disappearance of a 1.5-kb Hindlll genomic fragment and the generation of a 
2.3 kb restriction fragment when the respective ON and OFF phases were compared 
(71). 
It has been suggested that the insertion of a transposable element in the 
promoter region of the vspA is responsible for transcriptional regulation of vspA, 
resulting in the OFF phenotype.a The precise mechanism of this event is not fully 
understood and the role of V sps in the pathogenesis and virulence of M. bovis is still 
elusive (71). 
Mycoplasma bovis and Mycoplasmal Mastitis 
Mastitis is the single most costly disease of dairy cattle. In the U.S., it accounts 
for an economic loss of over one billion dollars due to decreased milk production 
a Yogev, D. 1999. Personal communication. 
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alone. When other factors are considered, the total cost reaches close to two billion 
dollars. There are numerous types of microorganisms responsible for mastitis, but 
Mycoplasma bovis is one of the contagious bacteria which requires "special attention" 
because of its high prevalence of infection (90). 
Mycoplasmal mastitis is characterized by a sudden drop in milk production (22) 
or a decrease in the quality of milk produced (75). Other symptoms are a significant 
alteration in milk consistency (64), lack of response to antibiotic treatment (127), and 
quick spread of infection from one udder quarter to the others (20). Infection of M. 
bovis is independent of the stage of lactation, since dry cows can also develop the 
disease (64). In an infected herd, more than 20% of the cows are affected, with 
subclinical carriers shedding M. bovis through their milk (88). The secreted milk 
varies from watery to purulent and appears as a clear liquid with precipitate (22). 
Failure of the cow to recover from disease during the continuing lactation period is 
also typical of mycoplasmal mastitis. Cows which are permitted to lactate after 
infection never regain their previous milk production level (88). 
Host Response in the Udder 
The bovine mammary gland is thought to be more susceptible to mycoplasma 
infections than any other site, since it does not normally possess any resident 
microflora (44). Experimental work has shown that the bovine udder is infected 
upwards only through the teat canal (86). The teat canal is a mechanical barrier 
which is covered with keratin, inhibiting the proximal progression of bacteria. This 
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is the first line of defense against infections. Bacteria can be absorbed to keratin and 
then flushed out by exfoliation during the milking procedure. Therefore, it is 
thought that repeated milking is probably one of the most important anti-bacterial 
mechanisms of the bovine udder (29). 
When bacteria pass through the teat canal and enter the teat cistern, they 
encounter the second line of defense, consisting of cellular and humoral factors 
present in the tissues and mammary secretions. Leukocytes, mainly neutrophils, 
macrophages, and lymphocytes, and epithelial cells from ducts and alveoli are 
present in bovine mammary secretions. The proportions of each cell type depend on 
the stage of lactation and health status of the gland (28). 
During infection, most cows experience swelling in the quarters, indicative of 
damage to the mammary gland (64). The cellular proportion of neutrophilic 
granulocytes (neutrophils) approaches 99% as they are attracted to the udder by 
inflammatory chemotactic substances. The speed at which neutrophils mobilize is of 
crucial importance for the outcome of infection (51). Neutrophils entering the teat 
cistern, during inflammation, have increased phagocytic capacity compared with 
blood neutrophils (114). This competency can be impaired, however, by the 
ingestion of fat and casein, and by the low level of glycogen and oxygen in the milk 
(29). 
The four immunoglobulin isotypes present in the bovine mammary gland, IgG1, 
IgG21 IgA, and IgM, are produced at the site of infection or are serum-derived. Their 
concentrations are low in normal milk, but increase dramatically during mastitis 
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(33). Most IgG1 is transported from the serum, while IgA and IgM are produced by 
local plasma cells. IgG2 can be derived from either source. During inflammation, 
IgG1 and IgG2 leak passively from the serum into the mammary secretions as 
vascular permeability and entry of leukocytes increase (3). IgG2 is also transported 
by attachment to leukocytes as IgG2 receptors on neutrophils are up-regulated 
during passage from blood to milk (85). 
The interaction of M. bovis with these immune factors has been studied in vitro. 
It was shown that lg preparations alone, were not able to kill M. bovis in the absence 
of peripheral-blood neutrophils and alveolar macrophages. The macrophage cells 
were incapable of ingesting M. bovis in the absence of IgG1 and IgG21 while IgM had 
no effect. IgG2 was the only isotype which promoted killing by the neutrophils, as 
IgG1 and IgM appeared ineffective (57). 
Course of infection 
Depending on the dose of infection, there is an incubation period from two to 
six days, during which time shedding may also occur (62). Experiments 
determining the virulence of M. bovis have shown that the "incubation time" before 
clinical symptoms appear may be important in M. bovis disease; shedding of the 
organism during this time may promote an increased infection rate. Strains isolated 
from the milk of cows, which did not display any symptoms of mastitis, were 
injected into healthy udders. Each resulted in a severe clinical case of mastitis (89). 
Isolates from nasal swabs of clinically healthy calves were also able to infect the 
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udder (87). The affected quarters become atrophic after two weeks of infection (64). 
In clinically healthy cows, which were once affected by mastitis, shedding of M. 
bovis continued, operating as a reservoir for the organism (88). 
M. bovis is most likely to enter the udder during, or shortly after the milking 
process, when the canals are still open (65), with a limited number of organisms 
needed to establish colonization (13). An infective dose of 70 CFU of mycoplasma 
cells, when applied intracistemally, proved sufficient to enable colonization of the 
udder. Shedding from these cows could inflict clinical disease in mycoplasma-free 
animals which were put in proximity to the artificially infected cattle (89). 
Mycoplasma bovis is capable of producing sub-acute to acute inflammation in a 
variety of other dairy cattle organs, including the joints, and respiratory or genital 
tracts (124). Although M. bovis is often associated with arthritis, pneumonia, and 
genital disorders, this is usually when mycoplasmal mastitis already persists in a 
dairy herd (44, 45). 
Control and containment 
Since a typical mycoplasmal mastitis outbreak spreads rapidly (24, 70), there is a 
resulting need to isolate or cull infected animals from the herd (127). This is no easy 
task as, to the best of the candidate's knowledge, there have only been two reported 
cases where the successful elimination of M. bovis from a herd was achieved (14, 23). 
There are some indications that prior exposure to M. bovis can reduce the 
severity and duration of experimental and natural infection (11, 12). There has been 
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some success with resistance to M. bovis infection in the respiratory tract by 
inoculation with inactivated organisms (58). But, as with all mycoplasmas (37), the 
many efforts to develop an effective and safe vaccine for M. bovis have been largely 
unsuccessful (19). 
At present, no effective immuno-protective measures against M. bovis are 
available (112). Although M. bovis is susceptible to a number of in vitro antibiotics, 
including tylosin, turimycin, spectinomycin, lincomycin, oxytetracycline, tiamulin, 
and enrofloxacin (123), these antibiotic drugs do not maintain their efficacy in vivo, 
and are not applicable for therapeutic purposes (63). 
A primary focus to controlling infection lies in management practices (20). The 
risk of first infection, rapidity of spread, and effectiveness of control is determined 
by milk sanitation procedures (90). Disinfectant solutions based on formalin or 
peracetic acid can kill M. bovis. Although the efficacy of any disinfectant will be 
reduced in the presence of a biological material, such as milk and nasal or genital 
discharge (59), these disinfectants have been found to be very effective in a short 
amount of exposure time (88). Iodophores are also known to be effective and are 
recommended for teat dipping (66). Unfortunately, most disinfectants used during 
milking, and for the sterilization of milking machines, are based on hypochlorides. 
These have proven to be unsuitable because relatively high concentrations and long 
exposure periods are required to kill M. bovis (88). 
In addition to specific control measures, prevention of M. bovis infections 
require a high standard of veterinary hygiene (112). Milking cows treated for 
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bacterial mastitis have commonly developed mycoplasma mastitis as a result of 
poor management techniques. Unsanitary treatment procedures during "drying-
off" after milking have been shown to be responsible for mycoplasma mastitis (62). 
Since shedding of M. bovis occurs at 103 to 106 CFU I ml before clinical symptoms are 
detected (88), there are many milking components which are vectors for 
transmission. The hands of the milker, cloths used to wipe the udder, and milking 
machines can all be factors which contribute to the spread of M. bovis within the 
herd (90). 
Importance of Mycoplasma bovis diagnosis in routine testing 
Detection of M. bovis at an early stage of infection has been shown to have a 
lower resulting impact on a herd (38). Disease as a result of M. bovis, including 
either mastitis or arthritis, can vary from 10%, if effective control measures are 
taken, to 50%, with inadequate measures (88). Due to a lack of effective treatments, 
maintaining herds free of Mycoplasma is the best solution (20). Because of the serious 
herd problems which may result, most cows infected with M. bovis are sent for 
slaughter (90). This mortality is another major economic loss for the farmer as 
he/ she looses potential milk production and resale value (5, 54). 
To a clean herd, the most likely source of mycoplasma infection is the 
introduction of infected cows (64). It is recommended that when new individual 
cows are purchased, at a minimum, the source-herd's bulk tank should be sampled 
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for M. bovis prior to introduction. In addition, it is recommended that in closed, 
clean herds, weekly bulk tank analysis is performed (20). 
Worldwide, there are currently many organizations present which perform 
routine testing of dairy herds (88). In the U.S., the Dairy Herd Improvement 
Association has a program to collect milk samples from individual and bulk tanks 
for somatic cell counts (90). Unfortunately, most programs do not currently test for 
the presence of mycoplasmas during their routine bacterial examination (88). This is 
unfortunate, as the prevalence of Mycoplasma varies between 1 and 4% for bulk tanks 
in which testing is performed (61). 
Detection Methods for Mycoplasma bovis 
Seventy to eighty percent of all milk production losses are associated with 
subclinical mastitis (90). The highly virulent and pathogenic nature of M. bovis 
creates a demand for early identification of infected tanks and individuals. Until 
immunology-based preventive methods become successful, the best method 
available for controlling mastitis involves the use of preventative measures to limit 
infection, and the culling of shedders once M. bovis has been detected. There is 
clearly a need for rapid and sensitive diagnostic methodologies for detecting M. 
bovis. 
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Culture and serology 
Routine diagnosis of M. bovis infection has been performed primarily by culture 
methods following mycoplasma isolation (44). The use of culture allows high 
sensitivity and specificity, ensuring reliable detection of M. bovis down to 101 to 102 
CFU I ml of biological sample (112). Bovine mycoplasma species differ widely in 
their nutritional demands for isolation (122), so this method is beneficial because it 
allows the possibility of detecting and isolating numerous species from one clinical 
sample (61). 
Culture is, however, very time consuming. Inoculated plates must be incubated 
at least two to three days before colonies may be observed and should not be 
considered negative prior to seven days of incubation (62). In addition, bacterial 
contamination of samples can be problematic (112). 
Capture-culture procedures using monoclonal antibodies (mAbs) have been 
developed to speed up the process of culture diagnosis. The method involves 
capturing the mycoplasmas in a pre-incubation, sandwich ELISA procedure (6). 
This is a less time-consuming method than culture, allowing the screening of a large 
number of samples, and providing results within three days (7). The sensitivity of 
these assays, dependent largely upon the monoclonal antibody used, is slightly 
lower than culture, at 105 to 103 CFU I ml milk (50). 
18 
Use of deoxyribonucleic acids 
Traditional culture methods require prudence when obtaining samples. Delays 
in processing can cause loss of sensitivity due to the death of the mycoplasma, or 
overgrowth of other bacteria (88). By using deoxyribonucleic acids for detection, it 
becomes possible to diagnose without the need of maintaining sample viability (55) 
These procedures targeted genes or genomic sequences specific for a particular 
group of infectious agents, a single species, or a particular strain. Originally, these 
sequences were selected, cloned, or synthesized and used as probes hybridizing on a 
dot blot with DNA or RNA of the clinical specimen (100). Several hybridization 
probes for M. bovis have been developed (78, 55), but these methods have had 
problems with M. bovis specificity, and were not found suitable for assaying 
biological samples (42). With sensitivity of only 105 to 106 CFU I ml, it was concluded 
that the selective binding of DNA to the membrane was severely disturbed by 
proteins and other substances present in milk (55). 
The introduction of polymerase chain reaction (PCR) has taken the DNA 
hybridization technique one step further, providing faster and much more sensitive 
tests. The sensitivity level of a PCR test can, in theory, be as low as a single 
organism, and PCR has the capability of copying a single, specific DNA sequence 
over a billion times within 3 hours (1). 
M. bovis PCR detection began by targeting uncharacterized random fragments 
of hybridization probes (55, 42). The amplification of rrs genes could detect 102 
CFU I ml of sample, and was the first DNA approach which targeted a specific 
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constitutive, housekeeping gene (43). Thus, it avoided the genetic variability that M. 
bovis type strain PG45 has displayed when compared with field isolates (10). 
However, this approach had problems with species-specificity as another closely 
related mycoplasma, M. agalactiae was also amplified with the organism (43). The 
165 rRNA regions of M. bovis and M. agalactiae have been shown to differ by only 8 
nucleotides (77). 
The most recent development of a PCR system for the detection of M. bovis 
involved the amplification of uvrC., a species-specific, constitutive protein (120). 
However, unlike the rrs assay, this study did not address the issue of sensitivity. 
Native substances in clinical samples can inhibit the PCR reaction (94), and so the 
method of DNA extraction is critical to the sensitivity of the PCR assay (118). Since a 
practical method must be able to detect low titers, and thus, subclinical carriers, the 
development of this DNA diagnostic assay should have included the testing of 
sensitivity on biological samples submitted for diagnostic purposes. 
Seven methods of DNA extraction were compared for their effectiveness in 
amplifying a M. bovis fragment used as a hybridization probe: cold phenol 
extraction, hot phenol extraction, lysozyme treatment, Tween-20 treatment, Triton X-
100 with membrane binding, pronase digestion, and a commercial DNA extraction 
kit. Of these, only use of Trition X-100 with membrane binding of DNA was found 
to be suitable for direct examination of milk containing clinical-threshold levels of 
M. bovis, at 106 CFU I ml. The detection limit of this assay was 500 CFU I ml, and the 
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results were available within 24 hours, making the procedure more rapid and 
sensitive than ELISA and culture techniques (56). 
Potential improvements to PCR for M. bovis detection. 
Cationic Surfactants. Cationic surfactants have the ability to lyse cells and 
precipitate nucleic acids, while rendering proteins soluble (72). The principle of this 
method is the structural configuration of an ammonium cation with the anionic 
nucleic acids to form a reverse micelle in an aqueous solution of low salt 
concentration (30). A precipitate forms as the cationic head group of the surfactant 
is attracted to the polyanionic nuclotides; the hydrophobic trimethyl side chains of 
the surfactant face the bulk phase (81). The reverse micelle is dissociated by raising 
the salt concentration, shifting the DNA to a soluble phase in the polar solvent (72). 
Coxiella burnetti, an obligate intracellular bacterium, has been detected by PCR 
in artifically contaminated cow's milk using the cationic surfactant 
cetyltrimethylammonium bromide (134). Application of 12 different cationic 
surfactants to mycoplasma detection in simulated lung samples has also been tested 
(68). However, these procedures, and commercially available cationic surfactant 
kits, have been limited in their ability to lyse cells completely (73 ). Their successful 
application has required the use of additional DNA extraction procedures (134, 68). 
A study of various cationic surfactants was conducted on whole blood to 
determine if these inadequaces could be overcome. It was found that the major 
determining factor in the ability to lyse cells and precipitate nucleic acids was the 
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counter ion of the cationic surfactant. Tetradecyltrimethylammonium oxalate was 
shown to be the most suitable of the cationic surfactants for nucleic acid isolation 
(73). The use of this particular surfactant as a stand-alone procedure has been 
effective in isolating nucleic acids for PCR in clinical blood (7 4) and fecal samples 
(132). 
Nested PCR. In addition to modifying the currently used DNA isolation 
procedures, another method for improving the sensitivity of PCR is by developing a 
"nested" reaction. This is a modification that has often been applied to cell culture 
or clinical material PCR systems in order to detect a single copy of target sequence 
(49). A first-round PCR is performed with a pair of outer primers, then a small 
amount of this product is transferred to a fresh reaction tube for a second-round of 
PCR by using a pair of primers which target the inner-region of the first-round 
product (48). The comparison of standard PCR and nested PCR on breast milk 
samples has shown nested to be 1000-times more sensitive for detecting human 
cytomegaloviral DNA (47). In addition to improving sensitivity, the nested PCR set 
serves to confirm the specificity of the first-round PCR (48). 
By implementing a cationic surfactant as a "one-step" DNA extraction method, 
and improving the sensitivity of PCR by using the nested approach, it would be 
possible to receive, process, and report diagnostic samples within the same working 
day. This would be the first practical method for routinely testing sub-clinical 
carriers of M. bovis, in order to target them for removal from the herd. 
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CHAPTER 3. DETECTION OF MYCOPLASMA BOVIS IN PRESERVATIVE-
TREATED FIELD MILK SAMPLES BY NESTED PCR AMPLIFICATION OF 
OLIGOPEPTIDE PERMEASE GENES 
A paper to be submitted to the Journal of Clinical Microbiology 
Cole C. Pinnow, Jenny A. Butler, Konrad Sachse, Helmut Hotzel, Leo Timms, and 
Ricardo F. Rosenbusch 
Abstract 
As the causative agent of mycoplasmal mastitis, Mycoplasma bovis is responsible 
for major economic losses. At present, the only method for combating the disease is 
good management practices involving the rapid identification and culling of all 
colonized cattle. Current techniques for identifying and detecting M. bovis are either 
laborious and time-consuming or unproven on clinical milk samples. In this paper, 
the development of a nested PCR method using cationic surfactant purification is 
described. A previously-described, randomly cloned DNA fragment was 
sequenced. This sequence information was used to develop a set of internal primers 
for a nested PCR assay. Cationic surfactant purification was used to eliminate 
substances which inhibit amplification, and seeded milk samples were used to 
determine a sensitivity of 0.85 CFU equivalents per ml of milk. Specificity of the 
nested PCR assay was confirmed and a comparison of culture, with blind passage, to 
the nested PCR reaction was performed on clinical field milk samples from M. bovis-
affected and M. bovis-free herds. Because it was possible to process samples within 
one working day, this is a practical procedure for M. bovis identification and would 
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allow for testing of both clinical and sub-clinical carriers using routinely obtained 
preservative-treated milk samples. 
Introduction 
As the causative agent of mycoplasmal mastitis (2, 17), Mycoplasma bovis causes 
considerable economic losses (5, 11, 33, 34). It has been shown that as few as 100 
mycoplasmas can colonize the udder and cause disease (4). Depending on the dose 
of infection , incubation period for M. bovis-induced disease can last from 2 to 6 days 
during which time shedding may occur (17). Also, chronically-infected cows can 
shed the organism for prolonged periods, long after clinical signs have subsided 
(27). Because no immunological-based treatment methods exist, present methods 
for controlling M. bovis involve preventative measures to limit infection, and the 
culling of shedders once M. bovis has been detected (29). The highly virulent and 
pathogenic nature of M. bovis creates a demand for the rapid identification of 
infected individuals (27), considering identification at an early stage of infection has 
been shown to have a lower resulting impact on a herd (8). 
The most commonly used methods for the diagnosis of M. bovis are detection by 
culture or capture-culture. These methods are time-consuming and often 
problematic because of non-mycoplasmal bacterial overgrowth (29). Inoculated 
plates must be incubated for at least two days, and should not be considered 
negative until seven days have passed (17). As a result, significant efforts have been 
made for the development of new M. bovis detection techniques, including the use of 
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DNA hybridization probes and PCR assays on milk samples for species-specific 
detection (10, 14, 23). 
The genome of M. bovis undergoes high-frequency rearrangements (22), which 
lead DNA-DNA hybridization differences between type strain PG45 and field 
isolates (3). Therefore, any M. bovis PCR assay must characterize the targeted 
genomic region and test field strains for compatibility. Although conserved gene-
specific PCR tests have been developed for the detection of M. bovis, none are 
practical for diagnostic purposes. Either there have been problems with specificity 
(26) or the issue of sensitivity was not addressed (30). 
Advancements in PCR methodologies are making it possible to detect specific 
pathogenic organisms directly in clinical samples with a sufficiently reduced 
processing time to have an impact in treating disease (28). There is a need for an 
approach which meets or exceeds the current sensitivity of PCR, but reduces the 
processing time of the sample. By implemented a procedure which will eliminate 
the problem of inhibitory protein in the milk sample without the application of 
lengthy and complex template preparation, it would be possible to conduct routine 
testing for M. bovis sub-clinical carriers, targeting them for removal from the herd. 
Materials and Methods 
Organisms and culture methods. The mycoplasmas and other bacteria used in 
this study are listed with references to their culture and media in Table 3.1. 
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Table 3.1. Results of the nested PCR reaction on reference strains using a 
commercial nucleic acid preparation from broth culture and the cationic surfactant 
purification from preservative-treated seeded milk samples. 
Strain no. Species Culture Origin Nucleic Seeded 
Media1 Acid Milk 
Template Template 
PG45 Mycoplasma bovis a ATCC 255232 + + 
M23 M. bovis a R. Rosenbusch + + 
PG51 Mycoplasma alkalescens e ATCC 29103 
GM139 Mycoplasma agalactiae a ATCC 35890 
PGll Mycoplasma bovigenitalium e ATCC 14173 
PG43 Mycoplasma bovirhinis a ATCC 27748 
M165/69 Mycoplasma bovoculi a ATCC 29104 
ST-6 Mycoplasma californicum g ATCC 33416 
Mycoplasma canadense e ATCC 29418 
462/2 Mycoplasma dispar a ATCC27140 
PG31 Mycoplasma gallisepticum d ATCC 19610 
PG21 Mycoplasma hominis f ATCC 23114 
Mycoplasma verecundum b ATCC27862 
PG50 Mycoplasma sp., bovine a ATCC 27367 
serogroup 7 
C492 Acholeplasma laidlawii c R. Rosenbusch 
Actinomyces pyogenes R. Griffith3 
Escherichia coli h R. Griffith 
Klebsiella pneumoniae h R. Griffith 
Pseudomonas aeruginosa h R. Griffith 
Serratia marcescens h R. Griffith 
Staphylococcus aureus h R. Griffith 
Streptococcus agalactiae R. Griffith 
Streptococcus disgalactiae R. Griffith 
Streptococcus uberis R. Griffith 
Field cases 
B55-50 M. bovis a Individual4 + 
B63-022 M. bovis a Individual + 
871-4143 M. bovis a Individual + 
B71-tg M. bovis a Bulk Tank5 + 
B71-r121 M. bovis a Individual + 
C496-bro M. bovis a Individual + 
C496-266 M. bovis a Individual + 
C496-202 M. bovis a Individual + 
C496-211 M. bovis a Individual + 
C496-g25 M. bovis a Individual + 
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Table 3.1. (continued) 
C496-242 M. bovis a Individual + 
C496-112 M. bovis a Individual + 
C496-y8 M. bovis a Individual + 
C496-276 M. bovis a Individual + 
C496-240 M. bovis a Individual + 
C496-259 M. bovis a Individual + 
C496-671 M. bovis a Individual + 
C496-82 M. bovis a Individual + 
C496-bktk M. bovis a Bulk Tank + 
C499-7859 M. bovis a Individual + 
C499-1211 M. bovis a Bulk Tank + 
C600-8 M. bovis a Bulk Tank + 
C600-9 M. bovis a Bulk Tank + 
C600-10 M. bovis a Bulk Tank + 
C600-11 M. bovis a Bulk Tank + 
C600-12 M. bovis a Bulk Tank + 
1 Media: a. modified Friis medium (20); b. modified Friis medium at pH 6.8;.c. Hayflick's broth (13); d. 
Hayflick's broth with 0.5% Glucose; e. Medium B (7) with 10% fetal bovine serum (FBS); f. SP4 (32) 
with 20% FBS; g. M96 (9) with 10% Horse Serum; h. Tryptic Soy Broth (Gibco BRL); i. TSB with 10% 
FBS. 
2 ATCC, American Type Culture Collection (Manassas, VA) 
3 Dr. R. Griffith, Department of Veterinary Microbiology and Preventive Medicine, Iowa State 
University, Ames, IA. 
4 Individual cow milk sample. 
5 Bulk tank milk sample. 
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Milk samples. Field milk samples were obtained from Iowa farms and from 
bovine mastitis cases submitted in 1996 to the Veterinary Medical Research Institute, 
Iowa State University. Upon receipt, all field milk samples were immediately 
cultured by blind passage, as described below. The samples were then frozen at 
-20°C. 
In 1998, the samples were thawed, cultured again, and prepared for nested PCR. 
To simulate submission of a bulk milk sample to the Dairy Herd Improvement 
(DHI) program, DHI milk preservative, which has an active ingredient of 18% 2-
bromo-2-nitropropane-1, 3-diol (Bronopol-Boots), was added at the mandated 1.69 
µl preservative per ml of milk sample. The samples were mixed until homogenous 
and then placed at 4 °C for 20 hours to insure killing of the mycoplasma. 
To determine the sensitivity of our assay, milk samples taken from a known 
negative cow were seeded with decreasing concentrations of M. bovis (strain PG45 or 
M23) and processed in the same manner as the field milk samples. The number of 
CFU of M. bovis reference cultures was determined by dilution plating as described 
(1). 
For culture, a 0.2 ml aliquot of each field milk sample was combined with 1.8 ml 
of modified Friis broth (20) and incubated at 37°C for 48 hours. This broth culture 
was streaked onto Friis plates, incubated at 37°C for 48 hours, and examined for M. 
bovis colony growth. 
Preparation of reference strains for PCR. Nucleic acids from log-phase culture 
were extracted with the QIAamp blood kit (Qiagen, Hilden, Germany) according to 
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the manufacturer's instructions for bacterial cultures, excluding the RNase step. A 
total of 1 µg of nucleic acids were used for nested PCR. 
Milk sample assay. A procedure for the rapid extraction of DNA from fecal 
samples was adapted (35). Briefly, the preservative-treated milk sample was 
vortexed until homogeneous. One ml of the sample was aliquoted to a 1.5 ml 
microfuge tube and 500 µl of sterile phosphate-buffered saline (PBS) was added. 
After a brief vortex, the sample was centrifuged at 14,000 x g for 20 min at room 
temperature. The supernatant was removed and the pellet was resuspended in 1 ml 
of PBS and centrifuged at room temperature for 10 min at 14,000 x g. One ml of the 
cationic surfactant Catrimox-14, tetradecyltrimethylammonium oxalate ( 6, 24) 
(Qiagen, Hilden, Germany), was used to resuspend the pellet until homogeneous. 
After an incubation of 10 min at room temperature, the sample was centrifuged at 
14,000xgfor10 min. The supernate was removed and the pellet was washed twice. 
A wash consisted of resuspending the pellet in 500 µl of distilled water and 
centrifuging for 10 min at 14,000 x g. After the final wash, the pellet was 
resuspended in 30 µl of distilled water. Five µl of this suspension was used as the 
template for the outer primer set of the nested PCR. 
DNA sequence. The 2 kb Hindlll insert into pUC19, previously described as 
pMB920 (14), was sequenced at the Iowa State University DNA facility using 
primers corresponding to the T3 and T7 promoters flanking the multiple cloning 
site. This was repeated so that the insert had been sequenced a total of 4 times (2 
forward, 2 reverse). The contiguous sequences were combined using the software 
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SeqEditor (Perkin-Elmer, Norwalk, CT) and the resulting sequence was analyzed 
using MacDNASIS (Hitachi Software, San Bruno, CA). Related nucleotide and 
amino acid sequences were searched for in GenBank, EMBL, DDBJ and PDB 
databases using BLAST and FAST A programs. A nested primer set was designed 
by using Oligo 4.0 (National Biosciences, Inc., Plymouth, MN) to search for target 
sites internal to the previously described primer pair PpMB920-1 and PpMB920-2 
(Table 3.2). 
Nested PCR. The outside PCR reaction used primers PpMB920-1 and 
PpMB920-2. Each tube had a total volume of 50 µl which contained 1 X PCR Buffer 
(Perkin-Elmer, Norwalk, CT}, 100 pM each primer, 200 µMeach deoxynucleotide 
triphosphate, 1.875 Units of AmpliTaq Gold polymerase (Perkin-Elmer), and 5 µl of 
template. After an initial denaturation step at 94°C for 11.5 min, the samples were 
run in an automated thermal cycler (PowerBlock II, Ericomp, Inc.} for 35 cycles of 
denaturation (94°C for 30 sec}, primer annealing (48°C for 60 sec} and extension 
(72°C for 150 sec). The final extension step was 5 min. The PCR product obtained, 
following amplification with the outside primer pairs, was diluted 1:100 and 5 µl 
was used as the template for the inside reaction. The inside reaction used primers 
PpSM5-1 and PpSM5-2. Each tube had a total reaction volume of 50 µl and 
contained the same concentration of reagents as the outside reaction. The cycling 
conditions for the inside reaction were an initial denaturing step at 94° for 11.5 min, 
followed by 30 cycles of 94°C for 45 sec, 54°C for 60 sec, and 72°C for 120 sec. The 
Table 3.2. Primer pairs used in nested polymerase chain reaction assay for the detection of M. bovis. 
Primers Nucleotide Sequence Annealing 
position a temperature 
PpMB920-2b 11-33 
PpMB920-1 1902-1921 
PpSM5-1 
PpSM5-2 
168-192 
581-609 
5' -TITT AGCTCTITITGAACAAAT-3' 
5' -GGCTCTCA TT AAGAATGTC-3' 
5' -CCAGCTCACCCTT ATACATGAGCGC-3' 
5' -GTGAAATAGTCGGTCTAATTGGTGAGTCA-3' 
a nt position according to GenBank accession number AF130119. 
b PpMB920-1 and PpMB920-2 were previously described (14). 
48°C 
54°C 
Fragment 
size 
1911 bp 
442bp 
(.>J 
0 
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final cycle had an extension for 5 min. Ten µl aliquots of the inside product were 
separated by electrophoresis in a 1.5% (wt/vol) agarose gel. The gel was then 
stained with ethidium bromide (0.5 µg /ml) for photography. Sensitivity was 
calculated by accounting for the sampling of 5 µl of the outer-reaction template, 
while not adjusting for the dilution of template for the inner-reaction. 
Results 
Sequence analysis. After accounting for stop codon assignment to Tryptophan, 
the DNA sequence of the 2004 bp M. bovis fragment in pMB920 (GenBank accession 
#AF130119) was shown to contain two partial open reading frames located on 
different coding regions. The first 471 bp encoded for a 156 aa portion of a protein' s 
C terminal region. The sequence contained a stop codon encompassed by a 
transcriptional stem-loop structure. The second open reading frame overlapped the 
first, and had an initiation codon beginning at 463 bp. This region of the sequence 
encoded for 514 aa, the N terminal portion of a protein, and was preceded by a 
ribosomal consensus sequence. 
Comparative analysis of the sequence using several gene bank databases 
showed there was 53.6% and 62.0% homology at the nucleic acid level with M. 
genitalium (GenBank EMBL accession #U39688) and M. hominis (GenBank EMBL 
accession #X99740), respectively. The deduced pair of open reading frames were 
found to correspond to the oppD and oppF genes in these organisms. Both oppD and 
oppF are oligopeptide permease genes, members of the ABC-transporter family 
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which encode for ATP-binding proteins. These ATPases provide energy for the 
transport of peptides across the membrane. Searching at the amino acid level 
showed that OppD and OppF in M. hominis had the highest degree of homology for 
known sequences. The M. bovis predicted amino acid sequences were 7 4.0% 
identical with the C-terminal region of OppD and 42.5% homologous with the N-
terminal region of OppF. 
Specificity and Sensitivity. After preliminary work in optimization of the PCR 
conditions using purified DNA, the established protocol amplified the expected 
region of M. bovis type strain PG45 and reference strain M23 to produce a specific 
442 bp product. Testing of the nested PCR protocol on the isolated nucleic acids 
from several non-M. bovis microorganisms did not result in any products (Table 3.1). 
The specificity of the reaction was not strain-specific, as the use of the nested PCR 
assay for the direct testing of 26 milk samples, containing M. bovis field strains, also 
resulted in the expected amplicon. The milk sample assay on seeded samples of 
non-M. bovis microorganisms did not produce any products. 
To determine the sensitivity of the nested PCR assay in preservative-treated 
milk, ten-fold serial dilutions of M. bovis were seeded and then processed according 
to the milk sample assay. As shown in Figure 3.1, the specific 442 bp product of the 
internal reaction could be amplified from preservative-treated milk containing 0.85 
CFU equivalents per ml. 
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Discussion 
The M. bovis fragment in pMB920 was previously shown to react in dot blot 
hybridization experiments with several field isolates (14). It was chosen as a target 
for further diagnostic PCR development because it was unlikely to contain a 
genomic target region which undergoes chromosomal rearrangements associated 
with phenotypic switching. As shown in Table 1 and Table 3, testing of the milk 
sample assay on 26 bulk and individual milk samples containing field strains 
reconfirmed that the targeted regions of oppD and oppF are conserved between 
strains and, therefore, do not undergo genomic rearrangements which would be 
observable by this procedure. 
The target locations of PpSMS-1 and PpSMS-2 were chosen based upon two 
criteria. First, they were designed to allow for an increased annealing temperature 
over PpMB920-1 and PpMB920-2, preventing erroneous cross-reacting primer pairs 
and multiple nested products. Second, the internal primers product results in the 
amplification of the intergenic region of the fragment. By targeting regions in two 
ORF, the possibility of amplifying RNA and DNA is avoided. It has been shown 
that primers targeting constitutive genomic regions have produced spurious 
products when DNA and RNA are used as the template (36). This was to be 
avoided since the method of template extraction in the milk assay procedure does 
not separate RNA from DNA. Therefore, when testing for specificity of the nested 
PCR, the RNase step was omitted from the template preparation. 
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specificity in the identification of M. bovis in hybridization experiments (14). The 
development of a nested PCR from this inserted fragment provided further 
improvement of specificity by not amplifying M. agalactiae, M. gallisepticum, and M. 
bovigenitalium (Table 3.1). Other mycoplasma species which have been isolated from 
cattle, or may be phylogeneticly related to M. bovis, did not cross-react with the 
nested PCR assay. In addition, other predominant bacteria which are associated 
with mastitis or might be found in milk samples were not amplified. Cationic 
surfactants do not lyse gram positive bacteria without the addition of a lysozyme 
pretreatment step (18). Even though the milk sample assay selectively prohibits 
PCR primers from accessing the DNA of these bacteria, any available nucleic acids 
from these organisms will not result in misdiagnosis. 
Cationic surfactant purification has been shown to be an effective and rapid way 
of eliminating the substances in clinical samples which inhibit PCR (19, 25). By 
lysing cells and precipitating nucleic acids in one step, the time for PCR template 
extraction is dramatically reduced, and the speed of diagnosis is improved. The 
total time taken to process and evaluate eight milk samples can be completed in 
under 10 hours, with the majority of this time accounted for by the automated PCR 
process. The time required for detection could be critical if there is a need to isolate 
or remove sub-clinical carriers. In addition, this assay was shown to work with 
preservative-treated milk. Therefore, it would be possible to process bulk or 
individual samples, destined for somatic cell counts, for the presence of M. bovis. 
Many herd improvement programs already collect samples on a routine basis, so 
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this method might be used in association with pre-existing evaluation procedures to 
enhance the sample results and give a clearer picture of the status of herd health. 
Single PCR amplifications may be ineffective for detection of low bacterial 
concentrations in cow milk samples (37). Components of milk samples can reduce 
the sensitivity of PCR to only 102-103 CFU equivalents per ml (31). Therefore, the 
development of a nested PCR primer set was used to improve sensitivity of the 
assay to identify subclinical carriers, which may be shedding low titers of M. bovis. 
The detected sensitivity of the milk sample assay was slightly lower than one viable 
cell per ml of milk sample. The use of the term CFU equivalents is needed, since 
several factors prohibit the determination of an "actual" mycoplasma cell number. 
First, although the seeded culture used was taken at log phase, non-viable cells were 
still present. Second, some aggregation of the mycoplasmas may have occurred, 
reducing the number of observable colonies used for determining CFU. Third, 
prokaryotes generally contain more than one chromosome equivalent per cell under 
exponential growth conditions (21), which would increase the number of available 
target sites for PCR. 
Despite these influencing factors which reduce the "actual" level of sensitivity, it 
still might be suggested that this detection assay for M. bovis is too sensitive. As 
with any type of assay, increase in sensitivity corresponds to an increase in the 
chance for false positive results. However, with good laboratory technique and 
proper controls, nested PCR can be used effectively in a diagnostic setting to provide 
accurate and repeatable results. If the high sensitivity of this assay is a concern, the 
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procedure can easily be amended to reduce the potential detection limit. The 
purpose of this study was not to present the definitive protocol for diagnostic use, 
but rather, to optimize a procedure showing the capability of M. bovis detection. 
By implementing a rapid approach to preparing clinical bovine milk samples 
and developing a nested approach to improve the sensitivity of a PCR system, this 
study has established the first practical procedure for the diagnostic detection of M. 
bovis. Because it was possible to process and provide a report on diagnostic samples 
within the same day, it was demonstrated that this procedure could be implemented 
in routine testing of preservative-treated samples for sub-clinical carriers. In this 
way, this nested PCR procedure can be effectively used as an adjunct in the 
establishment of M. bovis-free herds. 
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CHAPTER 4. GENERAL SUMMARY 
Mycoplasma bovis is one of the most important aetiological agents facing the 
dairy industry. As the causative agent of mycoplasmal mastitis, an infected 
individual will experience a drop in milk production, and act as a carrier by 
spreading the disease. Following infection cows never regain their previous 
production level of milk production. For this reason, cattle infected with M. bovis 
are usually sent for slaughter. Thus, M. bovis results in large economic losses to the 
farmer. 
The pathogenic nature of the M. bovis makes elimination of the organism from a 
herd difficult. It is thought that a family of variable surface lipoproteins (VSPs) play 
a role in the pathogenic success of M. bovis. These proteins have the ability to 
undergo phase and size variation, resulting in an extensive array of antigenic 
characteristics. Although the regulatory mechanisms controlling expression of VSPs 
is not understood, it is thought that these proteins enhance the colonization of host 
tissues and facilitate evasion of phagocytosis. 
Because immuno-preventative measures against M. bovis have been 
unsuccessful, good management practices are the best way to minimize the spread 
of M. bovis. Shedding of the organism occurs before clinical signs exist, resulting in a 
need to quickly identify all infected individuals for removal from the herd. In 
addition, subclinical carriers can shed infectious milk and are commonly introduced 
into herds without testing. Current techniques for identifying and detecting M. bovis 
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involve the use of deoxyribonucleic acids, specifically, PCR. This procedure has the 
potential to allow for specific and sensitive results, which are available more rapidly 
than culture methodologies. To date, most PCR identification procedures for M. 
bovis have been relatively laborious and time-consuming or were unproven on 
clinical samples. 
Identification and detection procedures for other organisms have shown that 
cationic surfactants and the development of a nested assay are two ways in which 
PCR can be improved for diagnostic purposes. Cationic surfactants lyse and 
precipitate nucleic acids in a rapid fashion. Nested PCR restores sensitivity which is 
often lost due to inhibitory substances in clinical samples. By implementing both of 
these methodologies, it was hoped that a practical procedure for the diagnostic 
detection of M. bovis would be achieved. 
In the accompanying manuscript, the development of a nested PCR method 
using cationic surfactant purification was described. Using seeded milk samples, it 
was determined that the sensitivity of the assay was 0.85 CFU equivalents per ml of 
milk. Specificity of the nested PCR was confirmed by using DNA from 26 other 
organisms. A comparison of the preservative-treated nested PCR assay and a 
standard culture assay was performed on clinical field milk samples from M. bovis-
affected and M. bovis-free herds. Because it was possible to process samples within 
ten hours, it was demonstrated that this procedure was practical for the routine 
testing of preservative-treated milk samples. In this way, this nested PCR procedure 
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can be effectively used as an adjunct in the establishment of M. bovis-free dairy 
herds. 
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APPENDIX A. STUDIES ON THE VIABILITY OF MYCOPLASMA BOVIS 
CULTURE SAMPLES 
The Effect of Freezing 
Detection of mycoplasmas by culture is often hampered by the care needed in 
obtaining and preserving diagnostic samples (88). This often results in a difficulty 
or failure in cultivation and a potentially missed diagnosis (116). In order to better 
illustrate the benefits of PCR over culture, supplemental work was performed to 
determine how the viability of M. bovis may be affected in milk samples submitted 
for culture. 
Milk samples were obtained from a collection of Iowa dairy farms and from 
cattle with mastitis which had been submitted in 1996 to the Veterinary Medical 
Research Institute, Iowa State University. Upon receipt, all raw milk samples were 
immediately cultured by blind passage, as described in Chapter 3. The remainder of 
each sample was then frozen at -20°C for two years. In 1998, the samples were 
thawed, and re-cultured prior to preparation for nested PCR. Nested PCR was 
performed in 1998 on 53 samples as described in Chapter 3. 
It is considered "good practice" to store milk samples in a refrigerator or freezer 
until they can be cultured (90). As Table A.l. shows, prolonged freezing can have a 
detrimental effect on the success of culture as a diagnostic method. Only 36.8% of 
the cultures remained viable during the 2 year storage. Although it is absurd to 
think that clinical samples would be stored for two years, the effect of freezing on 
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mycoplasma viability may play a role in misdiagnosis of sub-clinical M. bovis-
carriers. Further work could quantitatively determine the reduction in culture 
sensitivity with respect to storage time if culture remains the "gold standard" for 
definitive diagnosis. 
Application of the nested PCR method on preservative-treated milk samples 
showed that 1 % of the samples that were diagnosed as M. bovis-free with M. bovis 
went undetected by culture in 1996. All culture positive samples were also positive 
following application of the nested PCR assay. 
Table A.1. Observed results of culture on fresh and frozen field milk samples compared with the 
nested PCR assay after preservative-treatment. 
No. of Species Culture Culture Nested PCR 
Cases. 1996 1998 Result 
Field cases 
7 Mycoplasma bovis + + + 
19 M. bovis + + 
5 M. bovis + 
22 M. bovis 
The Effect of DHI Milk Preservative. 
The Dairy Herd Improvement Association has established a system of 
automated electronic cell counters which perform periodic somatic cell count reports 
on all milking cows. This count is performed on a monthly basis, sampling the total 
composite milk from all quarters of each cow enrolled in the program (90). After a 
milk sample is collected, a preservative is added to prevent possible bacterial 
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growth. To date, the characteristics of this preservative on microbial organisms 
have not been reported. a 
The toxic effect of DHI milk preservative, which has an active ingredient of 18% 
2-bromo-2-nitropropane-1, 3-diol (Bronopol-Boots), upon M. bovis was determined 
by titration as described in Chapter 3. Briefly, log phase M. bovis strain PG45 was 
used to seed milk from a known negative cow. The seeded milk was vortexed until 
homogenous and divided into two samples. One sample had the DHI preservative 
added at the mandated concentration of 1.69 µl per ml of milk. The two samples 
were homogenized and then placed in a 10°C water bath. Aliquots were taken every 
hour for titration plating on Friis agar. Three experiments were averaged and the 
concentration of M. bovis over time was calculated for the two samples. A toxicity 
curve was plotted (Figure A.1). 
The concentrations of mycoplasma remained relatively static in milk without 
preservative. The response to the disinfectant depended upon the initial 
concentration of mycoplasma and the period of contact. The use of DHI 
preservative in milk samples effectively killed a clinical concentration of M. bovis 
within 20 hours. Thus, the use of the DHI program for obtaining milk samples for 
diagnostic purposes must involve a procedure which does not depend on sample 
viability. 
• Timms, L. 1999. Personal communication. 
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Figure A.1. A plot of the time-survivor curve of Mycoplasma bovis 
exposed to the DHI milk preservative. An exponential death rate of 
y=45173974 x 10-o.3i 5x was found by fitting a curve to the treated results 
after hour 5. 
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APPENDIX B. THE INTERACTION OF VARIABLE SURFACE LIPOPROTEIN A 
(VSPA) IN MYCOPLASMA BOVIS WITH CULTURED MAMMALIAN CELLS 
In an attempt to further characterize the interaction of M. bovis with the host, the 
expression of VspA in the presence of mammalian cells was determined. An in vitro 
experimental model was developed to analyze whether vspA transcription was 
affected by incubation of M. bovis with different types of mammalian cells for 
various lengths of time. 
Rabbit antiserum, specific for epitopes of VspA (71), was prepared. Region RAl 
has the repetitive amino acid sequence of PGENKT. Region RA2 has the repetitive 
amino acid sequence of PEENKK. Region RA3 has the repetitive amino acid 
sequence of GTPANPDQ. The 13-amino acids of VspA comprising the sequence 
SDSDINPRIPHDD, is the part of the inter RA2-RA3 region of VspA which was found 
to be the most antigenic based upon computer analysis (Mac DNASIS v3.6, Hitachi 
Software, San Bruno, CA). These four haptens were synthesized (ISU Protein 
Facility, Ames, IA) directly onto their own multiple antigen peptide (MAP) cores 
(93, 121). After pre-inoculation sera were obtained, each antigen was injected into 
two rabbits. Each rabbit was injected a total of four times. On days 0 and 30, 250 µg 
was given in RIBI CWI adjuvant (RIBI ImmunoChem Res., Hamilton, MT). On days 
50 and 70, 1.2 mg of the antigen was emulsified with 1.4 ml of Freud's incomplete 
adjuvant (Sigma, St. Louis, MO) and injected in the same manner. The rabbits were 
bled on day 90 and the immunoglobulins were precipitated by ammonium sulfate 
procedure. All samples were analyzed by dot blot dilutions on native antigen to 
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determine titer and used in SOS-PAGE gel electrophoresis (113) against M. bovis 
strain PG45. 
Clonal isolates of strain PG45, described previously (71), were used to derive 
ON and OFF phase variants, which expressed or did not express VspA, respectively. 
Colony lifts of mycoplasmas plated on Friis medium agar were obtained using a .45 
µm HAWP membrane (Millipore Corp., Bedford, MA)and the VspA antiserum as 
previously described (69). Individual colonies expressing the desired phenotype 
were picked and grown in Friis broth at 37°C. At optimal turbidity, several aliquots 
were frozen at -70°C. These frozen aliquots were thawed at 37°C and immediately 
inoculated at 1:100 into warm Friis broth. After 20 hours at 37°C, dilutions of the 
broth suspension were inoculated onto Friis agar plates. Colony lifts were used to 
determine which frozen aliquots would result in a predominantly V spA ON 
phenotype and which colonies would express a predominantly V spA OFF 
phenotype after 20 hours incubation. Variant 22 was found to consistently generate 
90% colonies expressing VspA and variant 41 consistently generated 0% colonies 
expressing V spA. 
Both of these variants were added to culture tubes containing one several types 
of mammalian cells. They were incubated (with tumbling) at 37°C in mammalian 
cell media with 10% fetal bovine serum for 1, 2, and 3 hour intervals. The cell types 
used were a bovine monocyte cell line- BOMAC (National Veterinary Services 
Laboratories, Ames, IA), a bovine lung fibroblast cell line- BSL (R. Rosenbusch, Iowa 
State University, Ames, IA), MDBK (ATCC CRL# 6071), and Vero (ATCC 
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CRL#1586). Neutrophils (109) and monocytes (116) were isolated from bovine blood 
as previously described. Control reactions included reacting mycoplasma variants 
alone, and reacting mammalian cells alone, under the same conditions. The 
concentration of mycoplasma in each reaction was 1 x 107 CPU I ml while the 
mammalian concentration was 1 x 105 cells per ml. At the end of the incubation 
period, a ribonucleic acid protection assay (RP A) was used to establish the 
qualitative level of vspA mRNA. 
The Direct Protect lysate ribonuclease protection assay (Ambion Inc., Austin, 
TX) was used according to the manufacturer's instructions. RP A involved the lysis 
of the reaction mixture in guanidine thyocyanate (GuSCN), creating a cell lysate. 
The GuSCN-environment inhibited nucleases and allowed for the direct 
hybridization of an anti-vspA mRNA probe and anti-165 rRNA probe, without the 
need for total RNA isolation. The radioactively labeled, single-stranded, anti-sense 
RNA probes, described below, were added to the solution and incubated for 5 
hours. A solution containing T1 RNase was added to digest all unhybridized single-
stranded RNA, including unhybridized probe. The mixture was precipitated, 
denatured, and run on an acrylamide gel containing 8 M Urea. The labeled probe 
was visualized by exposing the gel to autoradiography film. Analysis of the image 
was performed using the public domain NIH Image program (U.S. National 
Institutes of Health, Bethesda, MD). 
Two gels for each mammalian cell type had densitometry analysis performed. 
A densitometry value curve was determined for each gel and the ratio of vspA 
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transcription to 16S rRNA transcription was calculated. This process was repeated 
two additional times for each gel. The values were averaged so that one ratio of 
vspA mRNA to 16S rRNA was determined for the individual lanes in each gel. 
These individual ratios were used in a split-plot design to calculate a table of means 
and an analysis of variance table (SAS v.6.12, SAS Inst., Cary, NC). 
The anti-sense probes were created with the MAXIscript in vitro transcription kit 
(Ambion Inc., Austin TX), using a PCR product as the DNA template. Analysis of 
the vspA sequence (71) was performed, using Oligo 4.0 (National Biosciences, Inc., 
Plymouth, MN), to design PCR primers which targeted non-repetitive regions 
unique to vspA. The downstream primer was altered to encode for a T3 promoter 
site for recognition of the T3 RNA polymerase. The DNA template for the 16S rRNA 
probe was created in a similar manner. The downstream primer, MboR, of a 
previously published pair (43), was altered to encode for a T7 promoter site and 
renamed CP1956. Table B.l lists the primer sequences and the product sizes for the 
PCR amplification and RP A hybridization reactions. 
The vspA PCR reaction had a total volume of 100 µl which contained 1 x PCR 
Buffer (Perkin-Elmer, Norwalk, CT), 100 pM each primer, 200 µMeach 
deoxynucleotide triphosphate, 3.25 Units of AmpliTaq Gold polymerase (Perkin-
Elmer), and 4 ng of template. After an initial denaturation step at 94 °C for 11.5 min, 
the sample was run in an automated thermal cycler (PowerBlock II, Ericomp, Inc.) 
for 30 cycles of denaturation (94°C for 60 sec), primer annealing (54°C for 60 sec) and 
extension (72°C for 90 sec). The final extension step was 3 min. 
Table B.1. Primer pairs used to create template for in vitro transcription of antisense RNA probes. 
Primers Gene Sequence PCR RPA 
Target Product Product 
CP179 vspA 5' -AACCAGAGCCCGACAAAAATCCAG-3' 309bp 285 bp 
CP316 5' -GGATCCAATI AACCCTCACTAAAGGGA TICTIGGGTTI AT-3' (Jl 
~ 
CP1957 16SrRNA 5' -CCTITI AGATIGGGATAGCGGATG-3' 360bp 336 bp 
CP1956 5' -GGATCCT AATACGACTCACTATAGGGT AGCATCA TTICCTAT-3' 
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The 165 rRNA PCR had a total volume of 100 µland contained the same 
concentration of reagents as the vspA reaction, except that 2.5 Units of polymerase 
were used. The cycling conditions were an initial denaturing step at 94° for 11.5 
min, followed by 30 cycles of 94°C for 45 sec, 56°C for 60 sec, and 72°C for 120 sec. 
The final cycle had an extension for 3 min. 
Results from the anti-VspA peptide antisera analysis showed titers of 10-i.9 for 
the most reactive rabbits against R2A, inter 2-3, and R3A. The anti-R1A rabbit only 
approached 10-0·7• When analyzed with monoclonal antibodies by SDS-P AGE 
electrophoresis, VspA appears as a 63-65 kD band. However, when the serum 
against R3A was run against whole M. bovis antigen, a 63 kD, a 45 kD, and a 20 kD 
band were apparent. Testing of the inter 2-3 serum resulted in a 45 kD and a 20 kD 
band. All other antiserum samples were not analyzed due to their low titer to native 
antigen. These results do not question the specificity of the developed antisera, 
rather, they confirm the findings of other studiesa which have shown that the target 
epitopes for V sps can be significantly altered after denaturation by SDS. 
The antisense vspA probe was found to cross react with an unknown native 
RNA of Vero, neutrophil, and monocyte cells, as shown by the 285 bp product in 
lane A of Figure B.l. Repeated trials suggested that the homology of the vspA probe 
to the non-specific RNA was not exact, since the vspA probe only cross-hybridized 
50% of the time. However, increase of the incubation temperature during 
a Rosenbusch, R.F. 1999. Personal communication. 
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Figure B.1. Autoradiograph of 8 M Urea acrylamide gels after RP A of BSL, vero, 
neutophils, or monocytes with variant 41. Lane A: Mammalian cells without 
mycoplasma incubated for 1 hour. Lane B-D: Mammalian cells incubated with M. 
bovis for increasing time intervals. Lane B: incubated for 1 hour; Lane C: incubated 
for 2 hours; Lane D: incubated for 3 hours; Lane E: M. bovis incubated alone in 
mammalian media for 3 hours. 
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Table B.2. Treatment means of the ratio of variant 22 vspA mRNA to 165 rRNA for 
mammalian cell type and incubation time. 
Incubation Time (hours) 
Cell Type Control 1 2 3 
BO MAC 0.11968 0.15849 0.14615 0.15443 
BSL 0.15701 0.11507 0.44536 0.13169 
MDBK 0.11232 0.14176 0.14620 0.22340 
hybridization, from 37°C to 47°C or 57°C, had no effect on this non-specificity. An 
alternative explanation is that the non-specific RNA was not transcribed 
consistently. Both of these theories need further experimental validation. 
Table B.2 shows the mean densitometry results for those cell types which did 
not display cross-hybridization. Table B.3 shows the analysis of variance for those 
experiments. There was not significant evidence that transcription of vspA was 
altered by the presence of BSL, BOMAC, or MDBK cells by F-test. Figure B.2 shows 
a representative gel for variant 22; transcription of vspA was not reduced in the 
Table B.3. Analysis of variance of the individual ratios of variant 22 vspA mRNA to 
16S rRNA for mammalian cell type and incubation time. 
Source d.f. 
Gel 1 
Cell Type 2 
Gel*Cell Type 2 
Incubation Time 3 
Cell Type*Time 6 
Exp. Error 11 
SS 
0.00390 
0.02099 
0.28711 
0.05028 
0.11169 
0.12013 
MS 
0.00390 
0.01050 
0.01436 
0.01676 
0.01862 
0.01335 
F 
0.27 
0.73 
1.08 
1.26 
1.39 
P>F 
.65 
.58 
.38 
.35 
.31 
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Figure B.2. Autoradiograph of 8 M Urea acrylamide gel after RP A of BSL with 
variant 22 and resulting densitometry analysis of rRNA (336 bp) and vspA (285 bp) 
transcription.. Lanes A-C: BSL cells incubated with M. bovis for increasing time 
intervals. Lane A: incubated for 1 hour; Lane B: incubated for 2 hours; Lane C: 
incubated for 3 hours; Lane D: Control lane, M. bovis incubated alone in BSL media 
for 3 hours. 
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presence of BSL cells. The gel showing the interaction of BSL cells with M. bovis, in 
Figure B.l., is a typical negative result for variant 41; there is no transcription of 
vspA at any time during the course of the experiment. 
Phenotypic studies on attachment of M. bovis using this experimental design 
have shown that only 4 to 5 mycoplasmas adhere to the mammalian cells after 1 
hour of incubation (106). Although the attachment number increases as incubation 
time increases, it is safe to say that analysis of vspA transcription by RP A, as 
described here, only reflects what is occurring with non-attached mycoplasmas. 
BSL, BOMAC, and MDBK cells do not induce a change in vspA transcription in non-
attached mycoplasmas, attachment may be needed. 
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